Tscan Therapeutics is trading at $0.22, down 5.63%, with no clear cause identified as of 11:06 a.m. EST on October 19, 2026. - A recent proxy filing proposes a 1-for-2 to 1-for-50 reverse split vote on November 20, following Nasdaq’s minimum-bid-price deficiency; available information does not establish that the filing caused the move. - Biotech and broader markets were reported higher, so the decline does not appear to track their direction.